You are here: Home: Audio Program Guide: Tissue Biomarkers in the Management of Breast Cancer 2008 | Audio: Tissue Biomarkers in the Management of Breast Cancer 2008
 
  Go to Challenges in HER2 Testing and Interpretation
Go to Assessment of Estrogen Receptor Status
Go to Evolving Role of Genomic Assays in Breast Cancer
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
  Challenges in HER2 Testing and Interpretation  
  Click here to download the entire interview  
Track 1 Case discussion (Dr Wolff): A 45-year-old premenopausal woman with de novo, symptomatic metastatic breast cancer (mBC) initially misclassified as ER-positive, HER2-negative
Track 2 Reassessment of ER and HER2 status at the time of cancer relapse
Track 3 Aims of the ASCO/College of American Pathologists (CAP) guidelines for HER2 testing
Track 4 Timing of tissue acquisition and processing in biomarker assessment
Track 5 Challenges in establishing quality control measures for HER2 testing
Track 6 Variability in HER2 results from local and large commercial laboratories

Track 7 Reliability and accuracy of HER2 via FISH
Track 8 Laboratory volume of HER2 testing as a surrogate measure of reliability and accuracy
Track 9 Frequency of IHC 2+ results from a laboratory as a measure of reliability in HER2 testing
Track 10 CAP ongoing proficiency program for HER2 testing
Track 11 “Tumor classification migration” phenomenon in an era of rapidly evolving diagnostic technologies
Track 12 Improvement of biomarker assessment without centralized testing and regulation
Track 13 Assessment of HER2 via reverse transcription-polymerase chain reaction (RT-PCR)
Track 14 Chromogenic in situ hybridization (CISH) assay for HER2 testing
Track 15 Central role of the HER2 protein in determining the biologic characteristics of tumors
Track 16 HERmark™ assay for quantitation of total HER2 protein levels and percentage of HER2 homodimers
Track 17 Current limitations of newly emerging HER2 assays
Track 18 Implications of false-negative versus false-positive HER2 results

Track 19 Implementing CAP recommendations for HER2 testing at individual institutions
     
  Assessment of Estrogen Receptor Status  
  Click here to download the entire interview  
Track 1 A comparison of ER measurement by ligand binding, IHC and quantitative RT-PCR
Track 2 Relationship between the method of ER assessment and clinical outcome
Track 3 ER and PR status in ECOG-E2197: Comparison of IHC by local and central laboratories and quantitative RT-PCR by central laboratory
Track 4 Relationship between quantitative ER/PR levels and response to hormonal therapy
Track 5 Role of quantitative ER assessment in clinical decision-making for patients with intermediate Recurrence Scores® on the Oncotype DX® assay
Track 6 Future role of RT-PCR for ER and PR in clinical practice

Track 7 Tissue prognostic factors for ER-positive breast cancer after neoadjuvant endocrine therapy
Track 8 Preoperative Endocrine Prognostic Index (PEPI)
Track 9 Validating intermediate surrogate markers of long-term outcome in the neoadjuvant setting
Track 10 Case discussion (Dr Budd): A 52-year-old premenopausal woman with a 2.1-cm, Grade I, strongly ER-positive, weakly PR-positive, HER2-negative, node-negative IDC and a Recurrence Score of 11
Track 11 ER and PR as prognostic and/or predictive factors
Track 12 Changes in ER and/or HER2 status from the primary to a relapsed or metastatic tumor

Track 13 Challenges and considerations in biopsying metastases for biomarker reassessment
Track 14 Therapeutic strategies to reverse acquired resistance to endocrine therapy
Track 15 Biopsy for confirmation of the diagnosis of mBC and treatment decision-making
Track 16 Intratumoral heterogeneity of HER2 expression and consequences for clinical management
Track 17 Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and metastases
     
  Evolving Role of Genomic Assays in Breast Cancer  
  Click here to download the entire interview  
Track 1 Contribution of Oncotype DX to clinical decision-making for three patients with intermediate Grade T1c, ER/PR-positive, HER2-negative early breast cancer
Track 2 ASCO 2007 update of recommendations for the use of tumor markers in breast cancer: Use of genomic assays
Track 3 FDA regulation and approval of genomic assays in breast cancer
Track 4 Tissue requirements and validation of the Oncotype DX and MammaPrint® assays
Track 5 Prognostic and predictive value of the Oncotype DX assay in postmenopausal, node-positive, ER-positive breast cancer
Track 6 Clinical utility of Oncotype DX for patients with node-positive breast cancer

Track 7 Applicability of Oncotype DX in the current treatment era of aromatase inhibitors and extended adjuvant endocrine therapy
Track 8 Methodology used in the development and validation of the Oncotype DX assay